Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients

Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat may be beneficial for patients who inadequately respond to erythropoiesis‐stimulating agents (ESAs). This post‐hoc analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Yamaguchi, Yusuke, Majikawa, Yoshikatsu, Reusch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451884/
https://www.ncbi.nlm.nih.gov/pubmed/33200512
http://dx.doi.org/10.1111/1744-9987.13609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451884/
https://www.ncbi.nlm.nih.gov/pubmed/33200512
http://dx.doi.org/10.1111/1744-9987.13609

Ejemplares similares